U.S. Department of Health and Human Services-Pharmaceuticals & Healthcare-Deals and Alliances Profile

U.S. Department of Health and Human Services-Pharmaceuticals & Healthcare-Deals and Alliances Profile


  • Products Id :- GDPH229804D
  • |
  • Pages: 186
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

U.S. Department of Health and Human Services (HHS) is a healthcare service provider that offers patient care and support services. The organization's service areas include health insurance marketplace, mental health, food safety, fighting HIV or AIDS, supporting military families, statistics, medicare fraud, and flu prevention. It also provides social services, prevention and wellness; providers and facilities; public health and safety; and emergency preparedness and response programs. The organization operates in Boston, District of Columbia, Atlanta, Chicago, Kansas City, Dallas, Denver, San Francisco, and Seattle. HHS is headquartered in Washington D.C., the US.

U.S. Department of Health and Human Services-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 11

U.S. Department of Health and Human Services, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 12

U.S. Department of Health and Human Services, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 13

U.S. Department of Health and Human Services, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 14

U.S. Department of Health and Human Services, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 15

U.S. Department of Health and Human Services, Medical Devices Deals, 2011 to YTD 2017 17

U.S. Department of Health and Human Services, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 18

U.S. Department of Health and Human Services, Pharmaceuticals & Healthcare, Deal Details 31

Venture Financing 31

Aura Biosciences Secures An Additional US$3 Million In Series A Financing 31

Partnerships 31

Abeome Enters into Research Agreement with Centers for Disease Control and Prevention 31

ConverGene Enters into Development Agreement with National Institute of Neurological Disorders and Stroke 32

Oncoceutics Enters into Research Agreement with National Institutes of Health 33

Cyprium Therapeutics Enters into Research and Development Agreement with Eunice Kennedy Shriver NICHD 34

Achieve Life Science and OncoGenex Pharma Enter into Partnership with National Institutes of Health 35

Emergent BioSolutions Enters into Agreement with Biomedical Advanced Research and Development Authority 35

Chrysalis BioTherapeutics Enters into Agreement with National Institute of Allergy and Infectious Diseases 36

Geneuro Enters into Agreement with National Institute of Neurological Disorders and Stroke 37

Agenus Enters into Agreement with National Cancer Institute 38

Threshold Pharma Enters into Agreement with National Cancer Institute 39

Syndax Pharma Enters into Co-Development Agreement with National Cancer Institute 39

Immunovia to Enter into Agreement with National Cancer Institute 40

Pfizer Enters into Agreement with National Cancer Institute 41

Epizyme Enters into Research Agreement with National Cancer Institute 42

Human Metabolome Technologies Enters into Agreement with National Institute on Aging 43

Atrin Pharma Enters into Agreement with National Cancer Institute 44

Synthetic Biologics Enters into Research Agreement with Centers for Disease Control and Prevention 44

NewLink Genetics Enters into Agreement with BARDA 45

Riptide Bioscience Enters into Agreement with National Cancer Institute 46

Emergent BioSolutions Enters into Agreement with Biomedical Advanced Research and Development Authority 46

PapGene Enters into Agreement with National Cancer Institute 47

Sanofi Pasteur Enters into Contract with US Department of Health and Human Services 48

Cellerant Therapeutics Enters into Contract with National Institutes of Health 49

The Medicines Company Enters into Agreement with BARDA 49

Protein Sciences Enters into Agreement with Biomedical Advanced Research and Development Authority 50

Biomedical Advanced Research and Development Authority Enters into Agreement with Takeda Pharma 51

Cellectar Biosciences Enters into Contract with National Cancer Institute 52

University of Pittsburgh Cancer Institute Enters into Contract with National Cancer Institute 53

Advanced Accelerator Applications Enters into Agreement with National Cancer Institute 53

Altimmune Enters into Contract Agreement with BARDA for NasoShield 54

Evolva Enters into Agreement with National Institute of Allergy and Infectious Diseases 55

RedHill Biopharma Enters into Agreement with NIAID 56

Emergent BioSolutions Partners with Biomedical Advanced Research and Development Authority 57

Agilis Biotherapeutics Partners with National Center for Accelerating Translational Sciences 57

Cellular Dynamics International Enters into R&D Agreement with National Eye Institute 58

Kite Pharma Enters into R&D Agreement with National Cancer Institute 59

Cerus Enters into Contract with Biomedical Advanced Research and Development Authority 59

Flatiron Health Enters into Research Agreement with US Food and Drug Administration 60

Inovio Pharma Partners with National Cancer Institute and Mayo Clinic 61

Basilea Pharmaceutica International Enters into Agreement with Biomedical Advanced Research and Development Authority 62

Altor BioScience Enters into Co-Development Agreement with National Cancer Institute 63

NantBioScience and NantKwest Enters into R&D Agreement with National Cancer Institute 64

GeoVax Labs Enters into Research Agreement with Centers for Disease Control and Prevention 64

Eagle Pharma Enters into Agreement with National Institutes of Health 65

Asterand Bioscience Enters into Contract Agreement with National Institutes of Health 66

PDS Biotechnology Enters into R&D Agreement with National Cancer Institute 67

New England Research Institutes Enters into Research Agreement with National Heart Lung and Blood Institute 68

Regen BioPharma Enters into Research Agreement with National Institutes of Health 68

RespireRx Pharma Enters into Research Agreement with National Institute of Drug Abuse 69

OriGene Technologies Enters into Contract with National Cancer Institute 70

SolaranRx Enters into R&D Agreement with National Cancer Institute 71

Kite Pharma Enters into Research and Development Agreement with National Cancer Institute 72

Precision Biologics Enters into R&D Agreement with National Cancer Institute 72

Cancer Targeted Technology Enters into Contract Agreement with National Cancer Institute 73

GlaxoSmithKline Enters into Research Agreement with NIAID 74

Cerulean Pharma and AstraZeneca Enter into Research Agreement with National Cancer Institute 75

PepTcell Enters into Research and Development Agreement National Institute of Allergy and Infectious Diseases 76

Vaxart Enters into Contract with BARDA 77

SNBL USA Enters into Contract with BARDA 77

Saint Louis University Enters into Agreement with National Institutes of Health 78

SRI International Enters into Biological Testing Facility Contract with NICHD 79

KIYATEC Enters into Research Contract with National Cancer Institute 80

Vince & Associates Partners with US FDA Office of Generic Drugs 80

Protein Foundry Enters into Research Contract with NHLBI 81

SuviCa Enters into Contract with National Cancer Institute 82

SRI International Enters into Agreement with National Institute of Allergy and Infectious Diseases 83

Centers for Disease Control and Prevention Enters into R&D Agreement with Nanomedical Diagnostics 83

Pharma Product Development Enters into Agreement with BARDA 84

Galena Biopharma Enters into Agreement with National Cancer Institute 85

Regeneron Pharma Enters into Development Agreement with BARDA 86

WiCell Research Institute Enters into Distribution Agreement with NHLBI 86

Etubics Enters into R&D Agreement with National Cancer Institute 87

CDC Foundation Enters into Agreement with Pfizer and Centers for Disease Control and Prevention 88

GenSight Biologics Enters into Research Agreement with Pierre and Marie Curie University, INSERM and CNRS 89

Thrombolytic Science Enters into Agreement with National Institute of Neurological Disorders and Stroke 90

FirstString Research Enters into R&D Agreement with NCATS 91

Zydus Cadila Healthcare Enters into Research Agreement with National Institute of Allergy and Infectious Diseases 91

GenVec Enters into Research Agreement with LMIV 92

GeoVax Labs Enters into Research Agreement with National Institute of Allergy and Infectious Diseases 93

BioAegis Therapeutics Enters into Research Agreement with the National Institute of Allergy and Infectious Disease 94

Intrexon Enters into R&D Agreement with National Cancer Institute 94

Emergent BioSolutions Signs Agreement with Oxford University, GlaxoSmithKline and NIAID for the Production of an MVA Ebola Zaire Vaccine Candidate 95

Kite Pharma Amends R&D Agreement with National Cancer Institute for Cancer Immunotherapy Products 96

VistaGen Therapeutics Enters into R&D Agreement with National Institute of Mental Health 97

Lion Biotech Amends Co-Development Agreement with National Cancer Institute 98

MedImmune Enters into Co-Development Agreement with National Cancer Institute 99

Vtesse Enters into Agreement with National Institutes of Health for VTS-270 100

uBiome Enters into Research Agreement with Centers for Disease Control and Prevention 101

ArQule Enters into Co-Development Agreement with National Human Genome Research Institute for ARQ 092 101

Accelerate Diagnostics Enters into Co-Development Agreement with Centers for Disease Control and Prevention 102

GenSight Biologics Enters into Research Agreement with UPMC, INSERM and CNRS 103

Atox Bio Enters into Contract Agreement with BARDA for AB103 104

Kadmon Enters into R&D Agreement with NIDCR 105

Foamix Enters into Co-Development Agreement with National Eye Institute 106

New Amsterdam Sciences to Enter into Research Agreement with National Institute of Health 106

Paradigm Shift Therapeutics Enters into Agreement with National Cancer Institute 107

Organovo Enters Into Co-Development Agreement With National Center For Advancing Translational Sciences And National Institutes of Health 108

Lightlake Therapeutics Expands Co-Developmenet Agreement With National Institute On Drug Abuse 109

Lightlake Therapeutics Enters Into Co-Development Agreement With National Institute On Drug Abuse 110

National Cancer Institute Enters Into Co-Development Agreement With Seoul National University Hospital For Proteomic Technologies 111

Kite Pharma Enters Into R&D Agreement With National Cancer Institute For Cellular Immunotherapy Products 111

Cytori Therapeutics Amends its Agreement with Biomedical Advanced Research and Development Authority 113

Diurnal Extends Cooperative Research and Development Agreement with National Institutes of Health 114

DFH Pharma Enters Into Co-Development Agreement With NIAID For HIV Maturation Inhibitor Drugs 114

Rockland Immunochemicals Enters Into Co-Development Agreement With National Cancer Institute 115

ImmunoVaccine Enters into Research Agreement with National Institute of Allergy and Infectious Diseases 116

Delcath Systems Extends Co-Development Agreement With National Cancer Institute 117

FEI Enters Into R&D Agreement With NIH 118

DFH Pharma Enters Into Co-Development Agreement With National Cancer Institute 119

Raptor Pharma Enters Into Co-Development Agreement With NIDDK For RP104 120

Concert Pharma Enters Into Research Agreement With NIH 121

AVI BioPharma Enters Into Co-Development Agreement With National Institutes of Health For Exon 50 122

BN ImmunoTherapeutics Expands Co-Development Agreement With National Cancer Institute 123

Afraxis Enters Into Co-Development Agreement With National Institutes of Health 124

Aura Biosciences Enters Into Research And Development Agreement With NIH 125

Genesis Biopharma Enters Into Co-Development Agreement With The National Cancer Institute 126

Pharmacyclics Enters Into Co-Development Agreement With National Cancer Institute For PCI-32765 127

Viamet Pharma Enters Into Co-Development Agreement With National Institutes of Health 128

GNS Healthcare Enters Into An Agreement With National Cancer Institute 129

Amsterdam Molecular Enters Into Cooperative Research and Development Agreement With National Institutes of Health 130

New Zealand Pharma Enters Into Co-Development Agreement With National Human Genome Research Institute For DEX-M74 131

RRD International Enters Into Co-Development Agreement With National Institutes of Health Therapeutics For Rare And Neglected Diseases 132

Licensing Agreements 133

Selecta Biosciences Enters into Licensing Agreement with National Cancer Institute 133

NICHD Enters into Licensing Agreement with Cyprium Therapeutics 134

PaxVax Enters into Licensing Agreement with National Institutes of Health 135

ConverGene Enters into Licensing Agreement with National Center for Advancing Translational Sciences 136

Great Lakes Neuroscience Enters into Licensing Agreement with National Institutes of Health 136

Genesis Biopharma Enters Into Patent Licensing Agreement With National Institutes Of Health 137

Biologics Resources Enters into Licensing Agreement with National Institutes of Health 138

Medigen Vaccine Biologics Enters into Licensing Agreement with National Institutes of Health for Dengue Vaccine 139

Opiant Pharma Enters into Licensing Agreement with Walter Reed Army Institute of Research and National Institute on Drug Abuse 140

Kite Pharma Enters into Licensing Agreement with National Institutes of Health 140

Kite Pharma Enters into Licensing Agreement with National Institutes of Health 141

Butantan Institute Enters into Licensing Agreement with National Institute of Allergy and Infectious Diseases 142

Kite Pharma Enters into Licensing Agreement with National Institutes of Health 143

Lion Biotech Enters into Licensing Agreement with National Institutes of Health 144

Vtesse Enters into Licensing Agreement with National Institutes of Health for Cyclodextrins 144

Kite Pharma Enters into Licensing Agreement with National Institutes of Health for T Cell Receptor-Based Products 145

Exxell BIO Enters into Licensing Agreement with National Institute of Allergy and Infectious Diseases 147

Peptron Enters into Licensing agreement with National Institutes of Health 147

KannaLife Sciences Enters Into Licensing Agreement With NIH 148

Organic Vaccines Enters into Licensing Agreement with National Institutes of Health 149

Kite Pharma Enters into Licensing Agreement with National Institutes of Health for T Cell Receptor-Based Products 149

Aspyrian Therapeutics Enters Into Licensing Agreement With National Cancer Institute For Near-Infrared Photoimmunotherapy 150

Polyplus-transfection Enters into Licensing Agreeement with NIAID and NCI 151

Bavarian Nordic Enters into Licensing Agreement with National Institutes of Health 152

Radiation Control Technologies Enters Into Licensing Agreement With National Institutes of Health 153

NIH Center for Regenerative Medicine Enters Into Licensing Agreement With Horizon Discovery For Genesis Technology 153

KannaLife Sciences Enters Into Licensing Agreement With NIH-OTT 154

BioDigitalValley Enters Into Licensing Agreement With National Library of Medicine 155

BN ImmunoTherapeutics Enters Into Licensing Agreement With National Institutes of Health 155

Amsterdam Molecular Expands Licensing Agreement With National Institutes Of Health 157

NanoBio Enters Into Licensing Agreement With National Institutes Of Health 157

Ariadne Genomics Extends Licensing Agreement With NCI For Pathway Studio 158

Key Employees 160

Locations And Subsidiaries 161

Head Office 161

Other Locations & Subsidiaries 161

Recent Developments 164

Government and Public Interest 164

Dec 15, 2016: Department of Health and Human Services awards over $50 Million for new health center sites 164

Dec 01, 2016: Castro Announces $5.29M for UTSA Brain Health Research 165

Sep 15, 2016: HHS awards over $87 million for health centers IT enhancements 166

Sep 14, 2016: New data show major improvements in health care access, affordability, and quality under the Affordable Care Act 167

Sep 07, 2016: Molina Healthcare Announces Support for HHS Efforts to Improve the Marketplace Benefit and Payment Parameters 169

Aug 25, 2016: United States Surgeon General appeals to Americas clinicians to Turn the Tide on the prescription drug epidemic 170

Aug 18, 2016: HHS awards more than $100 million to improve health center quality 171

Aug 11, 2016: $10 Million in Grants Targets Community-Based Efforts to Combat Chronic Diseases in the Delta Region 172

Aug 04, 2016: HHS awards more than $8.6 million for Health Centers to Improve Care Coordination and Become Patient-Centered Medical Homes 173

Jul 26, 2016: Secretary Burwell Highlights Bundled Payments, Future of Delivery System Reform in Florida 174

Jul 25, 2016: Important Next Step towards a Better, Smarter, Healthier Medicare: New Payment Models and Rewards for Better Care at Lower Cost 175

Jul 20, 2016: HRSA Awards More Than $149 million to Grow the Nations Primary Care Workforce and Expand Health Professions Training 177

Jul 06, 2016: HHS announces new actions to combat opioid epidemic 178

Apr 18, 2016: Diabetes drug, metformin, lowers risk of heart disease deaths better than sulfonylureas 180

Mar 11, 2016: HHS awards $94 million to health centers to help treat the prescription opioid abuse and heroin epidemic in America 182

Product News 183

Feb 25, 2016: Medidatas Cloud Technology Powers U.S. Government Research on Drug Development Costs 183

Jan 19, 2017: Northwestern University: Clinical Trials Evaluate New Treatment for Anal Cancer 184

Other Significant Developments 185

Dec 05, 2016: CVS Health and HHS Study Finds Proactive Pharmacy-based Outreach Helps Patients Access Needed Medications during a Natural Disaster 185

Appendix 186

Methodology 186

About GlobalData 186

Contact Us 186

Disclaimer 186

List of Figures

U.S. Department of Health and Human Services, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1

U.S. Department of Health and Human Services, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1

U.S. Department of Health and Human Services, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1

U.S. Department of Health and Human Services, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1

U.S. Department of Health and Human Services, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 12

U.S. Department of Health and Human Services, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 13

U.S. Department of Health and Human Services, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 14

U.S. Department of Health and Human Services, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 15

U.S. Department of Health and Human Services, Medical Devices Deals, 2011 to YTD 2017 17

List of Tables

U.S. Department of Health and Human Services, Pharmaceuticals & Healthcare, Key Facts 1

U.S. Department of Health and Human Services, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 12

U.S. Department of Health and Human Services, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 13

U.S. Department of Health and Human Services, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 14

U.S. Department of Health and Human Services, Deals By Therapy Area, 2011 to YTD 2017 15

U.S. Department of Health and Human Services, Medical Devices Deals, 2011 to YTD 2017 17

U.S. Department of Health and Human Services, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 18

Aura Biosciences Secures An Additional US$3 Million In Series A Financing 31

Abeome Enters into Research Agreement with Centers for Disease Control and Prevention 31

ConverGene Enters into Development Agreement with National Institute of Neurological Disorders and Stroke 32

Oncoceutics Enters into Research Agreement with National Institutes of Health 33

Cyprium Therapeutics Enters into Research and Development Agreement with Eunice Kennedy Shriver NICHD 34

Achieve Life Science and OncoGenex Pharma Enter into Partnership with National Institutes of Health 35

Emergent BioSolutions Enters into Agreement with Biomedical Advanced Research and Development Authority 35

Chrysalis BioTherapeutics Enters into Agreement with National Institute of Allergy and Infectious Diseases 36

Geneuro Enters into Agreement with National Institute of Neurological Disorders and Stroke 37

Agenus Enters into Agreement with National Cancer Institute 38

Threshold Pharma Enters into Agreement with National Cancer Institute 39

Syndax Pharma Enters into Co-Development Agreement with National Cancer Institute 39

Immunovia to Enter into Agreement with National Cancer Institute 40

Pfizer Enters into Agreement with National Cancer Institute 41

Epizyme Enters into Research Agreement with National Cancer Institute 42

Human Metabolome Technologies Enters into Agreement with National Institute on Aging 43

Atrin Pharma Enters into Agreement with National Cancer Institute 44

Synthetic Biologics Enters into Research Agreement with Centers for Disease Control and Prevention 44

NewLink Genetics Enters into Agreement with BARDA 45

Riptide Bioscience Enters into Agreement with National Cancer Institute 46

Emergent BioSolutions Enters into Agreement with Biomedical Advanced Research and Development Authority 46

PapGene Enters into Agreement with National Cancer Institute 47

Sanofi Pasteur Enters into Contract with US Department of Health and Human Services 48

Cellerant Therapeutics Enters into Contract with National Institutes of Health 49

The Medicines Company Enters into Agreement with BARDA 49

Protein Sciences Enters into Agreement with Biomedical Advanced Research and Development Authority 50

Biomedical Advanced Research and Development Authority Enters into Agreement with Takeda Pharma 51

Cellectar Biosciences Enters into Contract with National Cancer Institute 52

University of Pittsburgh Cancer Institute Enters into Contract with National Cancer Institute 53

Advanced Accelerator Applications Enters into Agreement with National Cancer Institute 53

Altimmune Enters into Contract Agreement with BARDA for NasoShield 54

Evolva Enters into Agreement with National Institute of Allergy and Infectious Diseases 55

RedHill Biopharma Enters into Agreement with NIAID 56

Emergent BioSolutions Partners with Biomedical Advanced Research and Development Authority 57

Agilis Biotherapeutics Partners with National Center for Accelerating Translational Sciences 57

Cellular Dynamics International Enters into R&D Agreement with National Eye Institute 58

Kite Pharma Enters into R&D Agreement with National Cancer Institute 59

Cerus Enters into Contract with Biomedical Advanced Research and Development Authority 59

Flatiron Health Enters into Research Agreement with US Food and Drug Administration 60

Inovio Pharma Partners with National Cancer Institute and Mayo Clinic 61

Basilea Pharmaceutica International Enters into Agreement with Biomedical Advanced Research and Development Authority 62

Altor BioScience Enters into Co-Development Agreement with National Cancer Institute 63

NantBioScience and NantKwest Enters into R&D Agreement with National Cancer Institute 64

GeoVax Labs Enters into Research Agreement with Centers for Disease Control and Prevention 64

Eagle Pharma Enters into Agreement with National Institutes of Health 65

Asterand Bioscience Enters into Contract Agreement with National Institutes of Health 66

PDS Biotechnology Enters into R&D Agreement with National Cancer Institute 67

New England Research Institutes Enters into Research Agreement with National Heart Lung and Blood Institute 68

Regen BioPharma Enters into Research Agreement with National Institutes of Health 68

RespireRx Pharma Enters into Research Agreement with National Institute of Drug Abuse 69

OriGene Technologies Enters into Contract with National Cancer Institute 70

SolaranRx Enters into R&D Agreement with National Cancer Institute 71

Kite Pharma Enters into Research and Development Agreement with National Cancer Institute 72

Precision Biologics Enters into R&D Agreement with National Cancer Institute 72

Cancer Targeted Technology Enters into Contract Agreement with National Cancer Institute 73

GlaxoSmithKline Enters into Research Agreement with NIAID 74

Cerulean Pharma and AstraZeneca Enter into Research Agreement with National Cancer Institute 75

PepTcell Enters into Research and Development Agreement National Institute of Allergy and Infectious Diseases 76

Vaxart Enters into Contract with BARDA 77

SNBL USA Enters into Contract with BARDA 77

Saint Louis University Enters into Agreement with National Institutes of Health 78

SRI International Enters into Biological Testing Facility Contract with NICHD 79

KIYATEC Enters into Research Contract with National Cancer Institute 80

Vince & Associates Partners with US FDA Office of Generic Drugs 80

Protein Foundry Enters into Research Contract with NHLBI 81

SuviCa Enters into Contract with National Cancer Institute 82

SRI International Enters into Agreement with National Institute of Allergy and Infectious Diseases 83

Centers for Disease Control and Prevention Enters into R&D Agreement with Nanomedical Diagnostics 83

Pharma Product Development Enters into Agreement with BARDA 84

Galena Biopharma Enters into Agreement with National Cancer Institute 85

Regeneron Pharma Enters into Development Agreement with BARDA 86

WiCell Research Institute Enters into Distribution Agreement with NHLBI 86

Etubics Enters into R&D Agreement with National Cancer Institute 87

CDC Foundation Enters into Agreement with Pfizer and Centers for Disease Control and Prevention 88

GenSight Biologics Enters into Research Agreement with Pierre and Marie Curie University, INSERM and CNRS 89

Thrombolytic Science Enters into Agreement with National Institute of Neurological Disorders and Stroke 90

FirstString Research Enters into R&D Agreement with NCATS 91

Zydus Cadila Healthcare Enters into Research Agreement with National Institute of Allergy and Infectious Diseases 91

GenVec Enters into Research Agreement with LMIV 92

GeoVax Labs Enters into Research Agreement with National Institute of Allergy and Infectious Diseases 93

BioAegis Therapeutics Enters into Research Agreement with the National Institute of Allergy and Infectious Disease 94

Intrexon Enters into R&D Agreement with National Cancer Institute 94

Emergent BioSolutions Signs Agreement with Oxford University, GlaxoSmithKline and NIAID for the Production of an MVA Ebola Zaire Vaccine Candidate 95

Kite Pharma Amends R&D Agreement with National Cancer Institute for Cancer Immunotherapy Products 96

VistaGen Therapeutics Enters into R&D Agreement with National Institute of Mental Health 97

Lion Biotech Amends Co-Development Agreement with National Cancer Institute 98

MedImmune Enters into Co-Development Agreement with National Cancer Institute 99

Vtesse Enters into Agreement with National Institutes of Health for VTS-270 100

uBiome Enters into Research Agreement with Centers for Disease Control and Prevention 101

ArQule Enters into Co-Development Agreement with National Human Genome Research Institute for ARQ 092 101

Accelerate Diagnostics Enters into Co-Development Agreement with Centers for Disease Control and Prevention 102

GenSight Biologics Enters into Research Agreement with UPMC, INSERM and CNRS 103

Atox Bio Enters into Contract Agreement with BARDA for AB103 104

Kadmon Enters into R&D Agreement with NIDCR 105

Foamix Enters into Co-Development Agreement with National Eye Institute 106

New Amsterdam Sciences to Enter into Research Agreement with National Institute of Health 106

Paradigm Shift Therapeutics Enters into Agreement with National Cancer Institute 107

Organovo Enters Into Co-Development Agreement With National Center For Advancing Translational Sciences And National Institutes of Health 108

Lightlake Therapeutics Expands Co-Developmenet Agreement With National Institute On Drug Abuse 109

Lightlake Therapeutics Enters Into Co-Development Agreement With National Institute On Drug Abuse 110

National Cancer Institute Enters Into Co-Development Agreement With Seoul National University Hospital For Proteomic Technologies 111

Kite Pharma Enters Into R&D Agreement With National Cancer Institute For Cellular Immunotherapy Products 111

Cytori Therapeutics Amends its Agreement with Biomedical Advanced Research and Development Authority 113

Diurnal Extends Cooperative Research and Development Agreement with National Institutes of Health 114

DFH Pharma Enters Into Co-Development Agreement With NIAID For HIV Maturation Inhibitor Drugs 114

Rockland Immunochemicals Enters Into Co-Development Agreement With National Cancer Institute 115

ImmunoVaccine Enters into Research Agreement with National Institute of Allergy and Infectious Diseases 116

Delcath Systems Extends Co-Development Agreement With National Cancer Institute 117

FEI Enters Into R&D Agreement With NIH 118

DFH Pharma Enters Into Co-Development Agreement With National Cancer Institute 119

Raptor Pharma Enters Into Co-Development Agreement With NIDDK For RP104 120

Concert Pharma Enters Into Research Agreement With NIH 121

AVI BioPharma Enters Into Co-Development Agreement With National Institutes of Health For Exon 50 122

BN ImmunoTherapeutics Expands Co-Development Agreement With National Cancer Institute 123

Afraxis Enters Into Co-Development Agreement With National Institutes of Health 124

Aura Biosciences Enters Into Research And Development Agreement With NIH 125

Genesis Biopharma Enters Into Co-Development Agreement With The National Cancer Institute 126

Pharmacyclics Enters Into Co-Development Agreement With National Cancer Institute For PCI-32765 127

Viamet Pharma Enters Into Co-Development Agreement With National Institutes of Health 128

GNS Healthcare Enters Into An Agreement With National Cancer Institute 129

Amsterdam Molecular Enters Into Cooperative Research and Development Agreement With National Institutes of Health 130

New Zealand Pharma Enters Into Co-Development Agreement With National Human Genome Research Institute For DEX-M74 131

RRD International Enters Into Co-Development Agreement With National Institutes of Health Therapeutics For Rare And Neglected Diseases 132

Selecta Biosciences Enters into Licensing Agreement with National Cancer Institute 133

NICHD Enters into Licensing Agreement with Cyprium Therapeutics 134

PaxVax Enters into Licensing Agreement with National Institutes of Health 135

ConverGene Enters into Licensing Agreement with National Center for Advancing Translational Sciences 136

Great Lakes Neuroscience Enters into Licensing Agreement with National Institutes of Health 136

Genesis Biopharma Enters Into Patent Licensing Agreement With National Institutes Of Health 137

Biologics Resources Enters into Licensing Agreement with National Institutes of Health 138

Medigen Vaccine Biologics Enters into Licensing Agreement with National Institutes of Health for Dengue Vaccine 139

Opiant Pharma Enters into Licensing Agreement with Walter Reed Army Institute of Research and National Institute on Drug Abuse 140

Kite Pharma Enters into Licensing Agreement with National Institutes of Health 140

Kite Pharma Enters into Licensing Agreement with National Institutes of Health 141

Butantan Institute Enters into Licensing Agreement with National Institute of Allergy and Infectious Diseases 142

Kite Pharma Enters into Licensing Agreement with National Institutes of Health 143

Lion Biotech Enters into Licensing Agreement with National Institutes of Health 144

Vtesse Enters into Licensing Agreement with National Institutes of Health for Cyclodextrins 144

Kite Pharma Enters into Licensing Agreement with National Institutes of Health for T Cell Receptor-Based Products 145

Exxell BIO Enters into Licensing Agreement with National Institute of Allergy and Infectious Diseases 147

Peptron Enters into Licensing agreement with National Institutes of Health 147

KannaLife Sciences Enters Into Licensing Agreement With NIH 148

Organic Vaccines Enters into Licensing Agreement with National Institutes of Health 149

Kite Pharma Enters into Licensing Agreement with National Institutes of Health for T Cell Receptor-Based Products 149

Aspyrian Therapeutics Enters Into Licensing Agreement With National Cancer Institute For Near-Infrared Photoimmunotherapy 150

Polyplus-transfection Enters into Licensing Agreeement with NIAID and NCI 151

Bavarian Nordic Enters into Licensing Agreement with National Institutes of Health 152

Radiation Control Technologies Enters Into Licensing Agreement With National Institutes of Health 153

NIH Center for Regenerative Medicine Enters Into Licensing Agreement With Horizon Discovery For Genesis Technology 153

KannaLife Sciences Enters Into Licensing Agreement With NIH-OTT 154

BioDigitalValley Enters Into Licensing Agreement With National Library of Medicine 155

BN ImmunoTherapeutics Enters Into Licensing Agreement With National Institutes of Health 155

Amsterdam Molecular Expands Licensing Agreement With National Institutes Of Health 157

NanoBio Enters Into Licensing Agreement With National Institutes Of Health 157

Ariadne Genomics Extends Licensing Agreement With NCI For Pathway Studio 158

U.S. Department of Health and Human Services, Key Employees 160

U.S. Department of Health and Human Services, Other Locations 161

U.S. Department of Health and Human Services, Subsidiaries 161

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

U.S. Department of Health and Human Services, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license
Single User License
USD 250 INR 17250
Site License
USD 500 INR 34500
Corporate User License
USD 750 INR 51750

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com